COX-2 inhibitors
This article was originally published in The Tan Sheet
Executive Summary
"Concomitant use of aspirin may not fully offset" potential cardiovascular event risks of selective COX-2 inhibitors, Cleveland Clinic Foundation researchers report in the Aug. 22/29 JAMA. In examining the cardiovascular effects of the Rx drugs, Debabrata Mukherjee, MD, et al., looked at four trials, including the VIGOR study, which found a 2.38 relative risk of developing a thrombotic cardiovascular event with Merck's Vioxx (rofecoxib) compared with naproxen (1,000 mg/day). VIGOR study results "can be explained by either a significant prothombotic effect for rofecoxib or an antithrombotic effect from naproxen (or conceivably both)," Mukherjee et al. say
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning